Literature DB >> 35241250

CPET for Long COVID-19.

Robert Naeije, Sergio Caravita.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35241250      PMCID: PMC8884263          DOI: 10.1016/j.jchf.2022.01.008

Source DB:  PubMed          Journal:  JACC Heart Fail        ISSN: 2213-1779            Impact factor:   12.035


× No keyword cloud information.
In a recent issue of JACC: Heart Failure, Mancini et al report on cardiopulmonary exercise testing (CPET) in 41 patients with persistent dyspnea more than 3 months after recovery from a severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection. The main findings were disordered breathing and decreased peripheral oxygen extraction (EO2), much like reported in the myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Is this enough for a CPET phenotyping of post-acute sequelae of SARS-CoV2 infection, or long coronavirus disease-2019 (COVID-19)? The results of Mancini et al actually confirm those reported in 581 long COVID-19 patients from 11 studies, which we reviewed in June 2021. Our meta-analysis uncovered a hazy CPET profile with mild decrease in maximum O2 uptake (VO2), decreased anaerobic threshold, normal ventilation to carbon dioxide (VE/VCO2) slope on average but somewhat skewed to increased values, preserved ventilatory reserve and decreased EO2, all suggestive of deconditioning on the recovery of an acute inflammatory process, prolonged bed rest and post-traumatic syndrome (PST). Mancini et al go into detailed analysis of individual responses. This is prone to false-positive signals as CPET measurements are numerous and exposed to variability, particularly in middle-aged patients with comorbidities (which were noted in 31 of the reported patients). Comparing with matched controls rather than predicted values would have been preferable. Yet the patients showed erratic increases in respiratory rate, with early CPET tachypnea as typically seen in PTS. There also was a tendency to decreased peripheral EO2. This was wrongly calculated as arteriovenous O2 content differences (DavO2) divided by hemoglobin rather than by arterial O2 content, but characteristic anyway of deconditioning. Preload failure diagnosed in a subgroup of 7 patients disclosed vagotonic deconditioning as occurs in sedentary overweight subjects. Only 1 patient had upper limit of normal (at 1.97 WU) of pulmonary vascular resistance at exercise, not convincingly diagnostic of exercise-induced pulmonary hypertension. Long COVID-19 and ME/CFS are patient advocacy–derived entities. Generously funded research to uncover their physiologic or biologic determinants (since 1987 for ME/CFS) has failed until now. Admirable efforts such as those reported by Mancini et al should not distract from adequate attention to their dominant psychological components.
  2 in total

1.  Use of Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea Post-Coronavirus Disease.

Authors:  Donna M Mancini; Danielle L Brunjes; Anuradha Lala; Maria Giovanna Trivieri; Johanna P Contreras; Benjamin H Natelson
Journal:  JACC Heart Fail       Date:  2021-12       Impact factor: 12.035

2.  Phenotyping long COVID.

Authors:  Robert Naeije; Sergio Caravita
Journal:  Eur Respir J       Date:  2021-07-08       Impact factor: 16.671

  2 in total
  2 in total

1.  The effect of medium-term recovery status after COVID-19 illness on cardiopulmonary exercise capacity in a physically active adult population.

Authors:  Peter Ladlow; Oliver O'Sullivan; Alexander N Bennett; Robert Barker-Davies; Andrew Houston; Rebecca Chamley; Samantha May; Daniel Mills; Dominic Dewson; Kasha Rogers-Smith; Christopher Ward; John Taylor; Joseph Mulae; Jon Naylor; Edward D Nicol; David A Holdsworth
Journal:  J Appl Physiol (1985)       Date:  2022-05-19

2.  Predictors of Submaximal Exercise Test Attainment in Adults Reporting Long COVID Symptoms.

Authors:  Roman Romero-Ortuno; Glenn Jennings; Feng Xue; Eoin Duggan; John Gormley; Ann Monaghan
Journal:  J Clin Med       Date:  2022-04-23       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.